SC
RCUS icon

Schubert & Co’s Arcus Biosciences RCUS Stock Holding History

Schubert & Co’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11
Closed -$201 – 1174
2023
Q1 		$201 Sell
11
-12
-52% -$229 ﹤0.01% 1545
2022
Q4 		$476 Buy
23
+5
+28% +$138 ﹤0.01% 1400
2022
Q3 		$0 Buy
18
+2
+13% +$53 ﹤0.01% 1537
2022
Q2 		$0 Buy
16
+14
+700% +$343 ﹤0.01% 1563
2022
Q1 		$0 Sell
2
-1
-33% -$34 ﹤0.01% 1290
2021
Q4 		$0 Buy
+3
New +$116 ﹤0.01% 1236

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Schubert & Co's RCUS Position: Q2 2023 in Review

Schubert & Co sold out of Arcus Biosciences (RCUS) in Q2 2023, closing a stake of 11 shares — an estimated $201 sold.

Schubert & Co first reported a position in RCUS in Q4 2021 and held it in 6 quarters. The position peaked at $476 in Q4 2022. 181 funds tracked by Wall St. Rank hold RCUS as of Q2 2023.

  • Schubert & Co reported no remaining Arcus Biosciences position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 11 Arcus Biosciences shares in Q2 2023, an estimated $201.
  • Schubert & Co first reported a position in Arcus Biosciences in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Arcus Biosciences position peaked at $476 in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.